stockrowNeuraxis, Inc.
NRXS Healthcare Biotechnology
Neuraxis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, up 32.9% from fiscal 2024.
- Revenue
- +115.7%
- EPS
- +13.6%
- Free cash flow
- +29.8%
Quarter to June 2026, against a year earlier
Follow NRXS
Alert me
Neuraxis, Inc. (NRXS) EV/Sales
As of 6 November 2026, Neuraxis, Inc. (NRXS) trades at a EV/Sales of 12.8×. Over the past ten years it has ranged from 2.4× (October 2023) to 20.9× (May 2026); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.2× | 116.84% |
| FY2024 | 4.7× | (15.24%) |
| FY2023 | 5.5× | 23.69% |
| FY2022 | 4.5× | 0.00% |
| FY2021 | 4.5× | 0.00% |
| FY2020 | 4.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 15.1× | (12.56%) |
| Mar 2026 | 17.3× | 69.83% |
| Dec 2025 | 10.2× | 31.13% |
| Sep 2025 | 7.8× | 70.16% |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TNXP Tonix Pharmaceuticals Holding Corp. compare | −3.1× |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| TNYA Tenaya Therapeutics, Inc. compare | n/m |
| KZIA Novogen Limited compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| CLLS Cellectis S.A. compare | 0.2× |
| RANI Rani Therapeutics Holdings, Inc. compare | 12.6× |
| NRXS Neuraxis, Inc. | 12.8× |
| ATRA Atara Biotherapeutics, Inc. compare | 17.7× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)